[go: up one dir, main page]

AU2001277731A1 - Fused bicyclic amide compounds and medicinal use thereof - Google Patents

Fused bicyclic amide compounds and medicinal use thereof

Info

Publication number
AU2001277731A1
AU2001277731A1 AU2001277731A AU7773101A AU2001277731A1 AU 2001277731 A1 AU2001277731 A1 AU 2001277731A1 AU 2001277731 A AU2001277731 A AU 2001277731A AU 7773101 A AU7773101 A AU 7773101A AU 2001277731 A1 AU2001277731 A1 AU 2001277731A1
Authority
AU
Australia
Prior art keywords
fused bicyclic
amide compounds
medicinal use
bicyclic amide
medicinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001277731A
Inventor
Kenji Chiba
Takafumi Kawaguchi
Youichiro Naito
Makio Ohtsuki
Naoki Sugiyama
Hiroyuki Ushio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Welfide Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Welfide Corp filed Critical Welfide Corp
Publication of AU2001277731A1 publication Critical patent/AU2001277731A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/86—Benzo [b] furans; Hydrogenated benzo [b] furans with an oxygen atom directly attached in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001277731A 2000-08-09 2001-08-09 Fused bicyclic amide compounds and medicinal use thereof Abandoned AU2001277731A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000-241934 2000-08-09
JP2000241934 2000-08-09
PCT/JP2001/006852 WO2002012189A1 (en) 2000-08-09 2001-08-09 Fused bicyclic amide compounds and medicinal use thereof

Publications (1)

Publication Number Publication Date
AU2001277731A1 true AU2001277731A1 (en) 2002-02-18

Family

ID=18733040

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001277731A Abandoned AU2001277731A1 (en) 2000-08-09 2001-08-09 Fused bicyclic amide compounds and medicinal use thereof

Country Status (4)

Country Link
US (1) US7112594B2 (en)
EP (1) EP1310488A4 (en)
AU (1) AU2001277731A1 (en)
WO (1) WO2002012189A1 (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100852A1 (en) * 2001-06-13 2002-12-19 Genesoft Pharmaceuticals, Inc. Benzothiophene compounds having antiinfective activity
DE60330847D1 (en) * 2002-03-28 2010-02-25 Mitsubishi Tanabe Pharma Corp benzofuran
CA2478232C (en) * 2002-04-11 2011-06-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic amide derivatives as cytokine inhibitors
AU2003265382A1 (en) * 2002-08-23 2004-03-11 Pharmacia & Upjohn Company Llc Antibacterial benzoic acid derivatives
JP2005104838A (en) * 2003-01-09 2005-04-21 Tanabe Seiyaku Co Ltd Condensed furan compounds
EP1622866B1 (en) 2003-04-30 2012-07-25 Novartis AG Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators
TW200512181A (en) 2003-09-26 2005-04-01 Tanabe Seiyaku Co Amide-type carboxamide derivatives
TW200524915A (en) 2003-09-26 2005-08-01 Tanabe Seiyaku Co Carbamoyl-type benzofuran derivatives
US7417063B2 (en) * 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
JP2007536310A (en) * 2004-05-03 2007-12-13 ノバルティス アクチエンゲゼルシャフト Combination comprising S1P receptor agonist and JAK3 kinase inhibitor
CA2810655C (en) 2004-06-24 2013-12-10 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US8354427B2 (en) * 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
CN101084209A (en) * 2004-12-21 2007-12-05 德福根有限公司 Compounds with Kv4 ion channel activity
SE0403171D0 (en) * 2004-12-23 2004-12-23 Astrazeneca Ab New compounds
JPWO2006137350A1 (en) * 2005-06-22 2009-01-15 キッセイ薬品工業株式会社 Novel furopyridine derivatives, pharmaceutical compositions containing them and their use
JP2009521468A (en) * 2005-12-24 2009-06-04 バーテックス ファーマシューティカルズ インコーポレイテッド Quinolin-4-one derivatives as regulators of ABC transporters
DK1993360T3 (en) 2005-12-28 2017-05-22 Vertex Pharma SOLID FORMS OF N- [2,4-BIS (1,1-DIMETHYLETHYL) -5-HYDROXYPHENYL] -1,4-DIHYDRO-4-OXOQUINOLIN-3-CARBOXAMIDE
DE102006039038A1 (en) 2006-08-19 2008-02-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg New manufacturing process
JPWO2008108309A1 (en) * 2007-03-02 2010-06-17 協和発酵キリン株式会社 Fused pyridine derivative
EP2166846B1 (en) * 2007-06-20 2012-10-17 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
CN101778850A (en) * 2007-08-10 2010-07-14 H.隆德贝克有限公司 Heteroaryl amide analogs
BRPI0907162A2 (en) * 2008-01-11 2015-07-07 Univ California Compound, pharmaceutical composition and methods for activating procaspase performer 3, 6 and / or 7 and for treating a disease state in a mammal
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
EP2161266A1 (en) * 2008-08-22 2010-03-10 EVOTEC Neurosciences GmbH Benzofuran derivatives as orexin receptor antagonists
PL2349263T3 (en) 2008-10-23 2014-11-28 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
WO2010093808A1 (en) * 2009-02-11 2010-08-19 Reaction Biology Corp. Selective kinase inhibitors
HRP20151137T1 (en) 2009-03-20 2015-11-20 Vertex Pharmaceuticals Incorporated PROCEDURE FOR OBTAINING TRANSMEMBRANE CONTROLLER OF CYSTIC FIBROSE CONDUCTIVITY
WO2011024873A1 (en) 2009-08-26 2011-03-03 武田薬品工業株式会社 Fused heterocyclic ring derivative and use thereof
EP2471789B9 (en) 2009-08-26 2015-03-25 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
US8614208B2 (en) 2009-08-26 2013-12-24 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
CA2771833A1 (en) 2009-08-26 2011-03-03 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
DK3252057T3 (en) 2009-12-04 2024-06-17 Sunovion Pharmaceuticals Inc MULTICYCLIC COMPOUNDS AND METHODS OF USING THEREOF
EP2657230A4 (en) * 2010-10-14 2016-04-06 Mitsubishi Tanabe Pharma Corp AMIDE DERIVATIVE AND USE THEREOF
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
CA2817896A1 (en) * 2010-11-15 2012-05-24 Viiv Healthcare Uk Limited Inhibitors of hiv replication
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US20120184548A1 (en) * 2011-01-19 2012-07-19 Romyr Dominique Carboxylic acid aryl amides
IL265430B2 (en) 2012-02-27 2024-08-01 Vertex Pharma Pharmaceutical preparations containing a solid dispersion of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide and uses thereof
KR20150002661A (en) 2012-04-13 2015-01-07 미쓰비시 타나베 파마 코퍼레이션 Amidopyridine derivative, and use thereof
JP5925723B2 (en) * 2012-04-13 2016-05-25 田辺三菱製薬株式会社 Pharmaceutical use of amide derivatives
WO2016009253A1 (en) * 2014-07-16 2016-01-21 Anil Mishra Recombinant interleukin-15 is a therapeutic agent for the treatment of airway hyperactivity, resistance (obstruction) and fibrosis in chronic asthma
CN107250113B (en) 2014-10-07 2019-03-29 弗特克斯药品有限公司 Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator proteins
US10045981B2 (en) 2015-11-24 2018-08-14 Jakpharm, Llc Selective kinase inhibitors
AU2017301767A1 (en) 2016-07-29 2019-02-14 Pgi Drug Discovery Llc Compounds and compositions and uses thereof
CN116283877A (en) 2016-07-29 2023-06-23 赛诺维信制药公司 Compounds, compositions and uses thereof
CN110678205B (en) 2017-02-16 2023-05-23 桑诺维恩药品公司 Methods of treating schizophrenia
EP3655961A4 (en) * 2017-07-17 2021-09-01 Massachusetts Institute of Technology CELL ATLAS OF HEALTHY AND DISEASED BARRIER TISSUE
KR20200036008A (en) 2017-08-02 2020-04-06 선오비온 파마슈티컬스 인코포레이티드 Isocroman compounds and uses thereof
JP7453148B2 (en) 2018-02-16 2024-03-19 サノビオン ファーマシューティカルズ インク Salts, crystalline forms, and their production methods
MX2021010880A (en) 2019-03-14 2022-01-18 Sunovion Pharmaceuticals Inc SALTS OF AN ISOCHROMANIL COMPOUND AND CRYSTALLINE FORMS, PREPARATION PROCESSES, THERAPEUTIC USES AND PHARMACEUTICAL COMPOSITIONS THEREOF.
MX2022012833A (en) 2020-04-14 2022-11-07 Sunovion Pharmaceuticals Inc (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders.

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB760750A (en) 1953-05-28 1956-11-07 Bayer Ag Water insoluble monoazo dyestuffs
US3413308A (en) * 1966-09-02 1968-11-26 Dow Chemical Co Substituted benzo(b)thiophene-2-carboxanilides
US3479348A (en) 1967-11-14 1969-11-18 Sumitomo Chemical Co Quinoxaline derivatives
US4179578A (en) 1971-12-24 1979-12-18 Sandoz Ltd. Para-phenyl stilbene derivatives
DK408574A (en) 1973-09-06 1975-05-05 Ciba Geigy Ag
US4145364A (en) 1977-11-30 1979-03-20 Merck & Co., Inc. Preparation of fluorinated anilines
US4191775A (en) * 1977-12-15 1980-03-04 Imperial Chemical Industries Limited Amide derivatives
EP0023569B1 (en) * 1979-07-13 1983-06-22 Dr. Karl Thomae GmbH Derivatives of carboxylic acids, their preparation and medicaments containing them
DE2948056A1 (en) 1979-11-29 1981-06-04 Boehringer Mannheim Gmbh, 6800 Mannheim NEW AMINOPROPANOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
US4800211A (en) * 1986-08-18 1989-01-24 Merck & Co., Inc. 5-methylthio-3-hydroxybenzo [b]thiophene-2-carboxamide derivatives as cyclooxygenase and lipoxygenase inhibitors
US5268389A (en) 1989-10-16 1993-12-07 Uniroyal Chemical Company, Inc. Thiocarboxylate ester compounds compositions containing the same
US5023265A (en) 1990-06-01 1991-06-11 Schering Corporation Substituted 1-H-pyrrolopyridine-3-carboxamides
GB9816837D0 (en) 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
US5356926A (en) 1992-02-24 1994-10-18 Warner-Lambert Company 3-alkyloxy-, aryloxy-, or arylalkyloxy-benzo [β]thiophene-2-carboxamides as inhibitors of cell adhesion
DE4319041A1 (en) 1992-10-23 1994-04-28 Bayer Ag Trisubstituted biphenyls
JPH06298732A (en) 1993-02-16 1994-10-25 Taisho Pharmaceut Co Ltd Indole derivative
DE69412538T2 (en) 1993-05-18 1998-12-24 Takeda Chemical Industries, Ltd., Osaka Benzopyran derivatives and their use
DE4317076A1 (en) 1993-05-21 1994-11-24 Bayer Ag Benzothiophene carboxamide S-oxide
US5750702A (en) * 1993-10-27 1998-05-12 Neurogen Corporation Certain pyrrolo pyridine-3-carboxamides; a new class of GABA brain receptor ligands
US5484944A (en) 1993-10-27 1996-01-16 Neurogen Corporation Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands
US5631280A (en) * 1995-03-29 1997-05-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6514996B2 (en) 1995-05-19 2003-02-04 Kyowa Hakko Kogyo Co., Ltd. Derivatives of benzofuran or benzodioxole
DE19612506A1 (en) 1996-03-29 1997-10-02 Wella Ag Oxidation hair dyes containing 2,5-diaminobenzonitriles and new 2,5-diaminobenzonitriles
US5972936A (en) 1996-05-20 1999-10-26 Darwin Discover Limited Benzofuran carboxamides and their therapeutic use
DE69738949D1 (en) 1996-05-20 2008-10-09 Darwin Discovery Ltd CHINOLINE CARBOXAMIDES AS TNF INHIBITORS AND AS PDE IV INHIBITORS
JP4373497B2 (en) * 1996-06-19 2009-11-25 ローン−プーラン・ロレ・リミテツド Substituted azabicyclo compounds and their use as inhibitors of TNF and cyclic AMP phosphodiesterase production
ID21775A (en) * 1996-10-25 1999-07-22 Yoshitomi Pharmaceutical COMPOUND 1-PHENILPIRAZOL COMPOUNDS AND THE USE OF PHARMACIES
DE69723863T2 (en) * 1996-11-06 2004-04-15 Darwin Discovery Ltd., Slough CHINOLINE AND THEIR THERAPEUTIC USE
US6069151A (en) * 1996-11-06 2000-05-30 Darwin Discovery, Ltd. Quinolines and their therapeutic use
AU4967797A (en) 1996-11-19 1998-06-10 Kyowa Hakko Kogyo Co. Ltd. Benzofuran derivatives
AUPO395396A0 (en) 1996-12-02 1997-01-02 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
EP0946508B1 (en) 1996-12-23 2009-09-23 Bristol-Myers Squibb Pharma Company NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS
UY24949A1 (en) 1997-04-08 2001-04-30 Smithkline Beecham Corp CALCILITE COMPOUNDS
AUPO941497A0 (en) 1997-09-24 1997-10-16 Fujisawa Pharmaceutical Co., Ltd. Novel compounds
WO1999041239A1 (en) 1998-02-10 1999-08-19 Novartis Ag B cell inhibitors
AU2641299A (en) 1998-03-04 1999-09-20 Kyowa Hakko Kogyo Co. Ltd. Benzofuran derivatives
TW555759B (en) 1998-06-08 2003-10-01 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use
JP2002521408A (en) 1998-07-28 2002-07-16 スミスクライン・ビーチャム・コーポレイション Compounds and methods
IL141183A0 (en) * 1998-08-04 2002-02-10 Astrazeneca Ab Amide derivatives useful as inhibitors of the production of cytokines
JP2000095767A (en) 1998-09-28 2000-04-04 Takeda Chem Ind Ltd Antagonist for gonadotrophic hormone-releasing hormone
US6166028A (en) * 1998-12-09 2000-12-26 American Home Products Corporation Diaminopuridine-containing thiourea inhibitors of herpes viruses
DE60045474D1 (en) * 1999-01-13 2011-02-17 Univ New York State Res Found NEW METHOD FOR CREATING PROTEIN KINASE INHIBITORS
HK1046136A1 (en) * 1999-02-10 2002-12-27 三菱制药株式会社 Amide compounds and medicinal use thereof
WO2001021615A1 (en) * 1999-09-17 2001-03-29 Yamanouchi Pharmaceutical Co., Ltd. Benzimidazole derivatives
KR100312685B1 (en) 1999-09-28 2001-11-03 김순택 Beam index type cathode ray tube and method for making photodetector compatible with this cathode ray tube
WO2001028993A2 (en) * 1999-10-19 2001-04-26 Merck & Co. Inc. Tyrosine kinase inhibitors

Also Published As

Publication number Publication date
WO2002012189A1 (en) 2002-02-14
EP1310488A4 (en) 2005-08-10
EP1310488A1 (en) 2003-05-14
US20030203909A1 (en) 2003-10-30
US7112594B2 (en) 2006-09-26

Similar Documents

Publication Publication Date Title
AU2001277731A1 (en) Fused bicyclic amide compounds and medicinal use thereof
EP1367060A4 (en) Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
EP1364957A4 (en) Glycopyranosyloxypyrazole derivatives and medicinal use thereof
EP1364958A4 (en) Glycopyranosyloxypyrazole derivatives and medicinal use thereof
HUP0303103A3 (en) Fused pyrrolocarbazoles, pharmaceutical compositions containing them and use of the compounds
HUP0402236A3 (en) Heterocyclic compounds pharmaceutical compounds containing thereof and use thereof
AU2001264313A1 (en) Pyrazolopyridine compounds and use thereof as drugs
MXPA03004936A (en) Fused cyclic compounds and medicinal use thereof.
AU2001277741A1 (en) 2-aminopyridine compounds and use thereof as drugs
AU2001280188A1 (en) Pyrazolopyridine compound and pharmaceutical use thereof
AU2003291310A1 (en) Fused heterocyclic compounds and use thereof
AU2002354476A1 (en) Pyrazolopyridine derivatives and medicinal use thereof
AU2002218502A1 (en) Lactam compounds and medicinal use thereof
AU2002308891A1 (en) Novel heterocyclic derivatives and medicinal use thereof
PL367676A1 (en) Novel heterocyclic derivatives and medicinal use thereof
PL367639A1 (en) Novel heterocyclic compound and medicinal use thereof
AU2001261375A1 (en) Human caspase-12 materials and methods
AU2001290641A1 (en) Substituted fused pyrroleimines and pyrazoleimines
AU2001264273A1 (en) Amide compounds and use thereof
AU2000231564A1 (en) Phosphororganic compounds and the use thereof
AU4432001A (en) Trityl-type compounds and their use
AU6866700A (en) Biscyclopropanecarboxylic acid amide compounds and medicinal use thereof
AUPR548601A0 (en) Pyrazolopyrazinecompound and pharmaceutical use thereof
AU2001264900A1 (en) Pharmaceutical use of fibulin-1
AU2002215923A1 (en) Use of medicaments